(1) 药效关联的癌症单细胞亚群识别与精准联合医疗研究，国家自然科学基金面上项目，主持，在研。

(2) 药物对动植物细胞作用机制研究，横向项目，主持，在研。

(3) 非小细胞肺癌不同KRAS突变型的治疗异质性与精准联合用药研究，国家自然科学基金面上项目，主持，结题。

(4) 基于高通量药物基因组学数据的肺癌个性化联合用药方案筛选和评估，国家自然科学基金面上项目，主持，结题。

(5) 头颈部恶性肿瘤个性化药物评价及临床转化体系建立，精准医学研究重点专项，参与，结题。

(6) 运用比较基因组学基于基因关系传递模式研究基因表达调控的进化机制，国家自然科学基金青年项目，主持，结题。

(7) miRNA在心脏和血管发育过程中的调控作用，973重大专项，参与，结题。

1. Tian P#, Zheng J#, Qiao K, Fan Y, Xu Y,Wu T, Chen S, Zhang Y, Zhang B, Ambrogio C, Wang H*. scPharm: Identifying pharmacological subpopulations of single cells for precision medicine in cancers. Advanced Science. 2024 Nov 19. Online publication.

2. Wu T#, Dai Y#, Xu Y, Zheng J, ChenS, Zhang Y, Tian P, Zheng X*, Wang H*. ExosomePurity: tumourpurity deconvolution in serum exosomes based on miRNA signatures. Briefings in Bioinformatics. 2023 May 19;24(3):bbad119.

3. Chen S#,Zheng J#, Zhang B, TangX, Cun Y, Wu T, Xu Y, Ma T, Cheng J, Yu Z*,Wang H*. Identification and characterization ofvirus-encoded circular RNAs in host cells. Microb Genom. 2022Jun;8(6):mgen000848.

4. Huang X, Xu Y, Qian L, Zhao Q, Liu P, Lü J, Guo Y,Ma W, Wang G, Li S, Luo A, Yang X, Wang H*,Yu Z*. Evolution of gene expressionsignature in mammary gland stem cells from neonatal to old mice. Cell Death Dis. 2022 Apr 12;13(4):335.

5. Xu Y, Zheng J, Cai Z, Li W, Köhler J, Dai Y, ChengX, Wu T, Zhang F, Wang H*. TherapeuticResponse-Based Reclassification of Multiple Tumor Subtypes Reveals IntrinsicMolecular Concordance of Therapy Across Histologically Disparate Cancers. Front Cell Dev Biol. 2021 Nov 12;9:773101.

6. Zheng J, Wang H*. Pharmaco-omics data sheds light on therapy-orientedprospects of precision medicine. EBioMedicine. 2021 Aug;70:103493(Commentary).

7. Dai Y, Cao Y, Köhler J, Lu A, Xu S*, Wang H*.Unbiased RNA-Seq-driven identification and validation of reference genes forquantitative RT-PCR analyses of pooled cancer exosomes. BMC Genomics. 2021 Jan6;22(1):27.

8. Cai Z#, Xue H#,Xu Y, Köhler J, Cheng X, Dai Y, Zheng J, WangH*. Fcirc: Acomprehensive pipeline for the exploration of fusion linear and circular RNAs. GigaScience.2020 Jun 1;9(6):giaa054.

9. Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-LópezG, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E,Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M*, Barbacid M*. Tumor regression andresistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lungadenocarcinomas. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426.

10. Luo A#, Xu Y#,Li S#, Bao J, Lü J, DingN, Zhao Q, Fu Y, Liu F, Cho WC, Wei X*, Wang H*, Yu Z*. Cancer stem cell property and gene signature inbone-metastatic Breast Cancer cells. Int J Biol Sci. 2020 Jul19;16(14):2580-2594.

11. Wang H*, Lv Q, Xu Y, Cai Z, Zheng J,Cheng X, Dai Y, Jänne P, Ambrogio C*, Köhler J*. An integrativepharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lungcancer. EbioMedicine. 2019 Nov;49:106-117.

12. Chen W, Wang J,Shi J, Yang X, Yang P, Wang N, Yang S, XieT, Yang H, Zhang M, Wang H*, Fei J*. Longevity Effect of Liuwei Dihuang in Both Caenorhabditis Elegans andAged Mice. Aging and Disease. 2019 Jun 1;10(3):578-591.

13. Liu R#,Wang J#, Ukai M, Sewon K,Chen P, Suzuki Y, Wang H*, Aihara K*, Okada-Hatakeyama M*, Chen L*. Hunt for the tipping point during endocrineresistance process in breast cancer by dynamic network biomarkers. J Mol Cell Biol. 2018 Nov 1. 

14. Ambrogio C*, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q,Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD*, Jänne PA*. KRAS Dimerization Impacts MEKInhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018 Feb 8;172(4):857-868.e15.

15. Liu Y, Fei T, Zheng X, Brown M, Zhang P*, Liu X*, Wang H*. An integrative pharmacogenomic approach identifiestwo-drug combination therapies for personalized cancer medicine. Sci Rep. 2016, 26:6.

16. Wang J, Lv Q, Li X, Liu Y, Liu K, Wang H*. Post-transcriptional andtranslational regulation modulates gene co-expression behavior in moresynchronized pace to carry out molecular function in the cell. Gene.2016, 587(2).

17. Zhang N#, Wang H#,Fang Y, Wang J*, Zheng X*, Liu X*.Predicting anticancer drug responses using a dual-layer integrated cellline-drug network model. Plos Computational Biology. 2015 Sep29;11(9).

18. WangH*#, Zheng X#, Fei T, Wang J, Li X, LiuY, Zhang F. Towards pathway-centric cancer therapies via pharmacogenomicprofiling analysis of ERK signalling pathway. Clin Transl Med. 2015Dec;4(1):66.

19. Wang J#,Zhang Y#, Wang H#, Dong N, Bao L, SunX, Xu M, Wang X*. Global analyses of subtype- or stage-specific genes onchromosome 7 in patients with lung cancer. Cancer Metast Rev. 2015 Jun;34(2).

20. WangH*, Meyer C, Fei T, Wang G, Zhang F*, Liu X. A systematic approachidentifies FOXA1 as a key factor in the loss of epithelial traits during theepithelial-to-mesenchymal transition in lung cancer. BMC Genomics. 2013, 14:680.

21. WangH*, Wang Q, Shen B and Li X*.Systematic investigation of global coordination among mRNA and protein incellular society. BMC Genomics. 2010, 11:364

22. WangH*#, Wang Q*#,Li X, Shen B, Ding M and Shen Z. Towards patterns tree of gene coexpression ineukaryotic species. Bioinformatics. 2008,24(11)：1367-1373.